Low-grade serous ovarian cancer (LGSOC) is a recurrent, chemotherapy-resistant cancer with a high mortality rate.1 It comprises 5-10% of serous ovarian cancers and 6-8% of all ovarian cancers.1 There are an estimated 6,000 patients in the U.S. and 80,000 worldwide living with this disease.2 LGSOC is most often diagnosed in women between the ages of 45-55 years1 and 85% of patients experience recurrence.3 Chemotherapy is the standard of care for this disease.1